Description: CVS posts a sharper MBR as PDR impacts ease and government business strengthens while maintaining a cautious full-year outlook.

Description: On November 25, 2025, Cencora Inc filed its annual 10-K report, detailing substantial financial growth and highlighting its acquisition of Alliance Healthcare to strengthen its global pharmaceutical distribution capabilities. The report also underscored Cencora's expanding opportunities in international markets and specialty pharmaceuticals, while noting increased operating expenses and ongoing litigation risks as important challenges. We'll now explore how Cencora's expanded international...

Description: Curious if Cencora stock still offers good value or if recent gains have pushed it out of reach? You are not alone in wondering whether now is the right time to take a closer look. Shares have been on the move, rising 2.2% in the past week and 64.0% year-to-date, building on an impressive 277.7% gain over the last five years. Recent headlines have highlighted Cencora’s expansive strategies, including major partnerships and sector-leading initiatives. These developments are fueling fresh...

Description: Cencora (COR) has shown a steady performance in recent weeks, catching the attention of investors who are watching for shifts in the healthcare distribution space. The stock’s trajectory offers an interesting lens into ongoing sector trends. See our latest analysis for Cencora. Cencora’s latest share price of $368.53 caps off an impressive run, with a 9.7% 1-month share price return and momentum continuing to build after recent sector tailwinds. Over the last year, shareholders enjoyed a...

Description: GE HealthCare unveils Genesis Radiology Workspace, aiming to streamline imaging workflows and boost diagnostic precision.

Description: Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Description: Here is how Cencora (COR) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Description: Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Description: Macy's climbs after a Zacks upgrade as multiple portfolios showcase strong gains across UNFI, Monster Beverage and other standout stocks.

Description: Shares of Cencora (COR) have been catching the attention of investors recently, with the stock showing marked movement over the past month and more than doubling in value across the past three years. Recent trading reflects a generally positive trajectory and has prompted closer inspection of what might be driving this performance. See our latest analysis for Cencora. Cencora’s share price momentum has steadily increased, notching a 14.8% gain over the past month and climbing 62.45%...

Description: Investors signalled that they were pleased with Cencora, Inc.'s ( NYSE:COR ) most recent earnings report. Looking...

Description: Cencora’s third quarter saw a positive market response, as the company delivered revenue and non-GAAP earnings that exceeded Wall Street expectations. Management pointed to strong growth in its U.S. Healthcare Solutions segment and the contribution of specialty pharmaceuticals as key drivers. CEO Robert Mauch emphasized that investments in areas like specialty distribution and recent acquisitions, such as Retina Consultants of America, enhanced the company’s value to both pharmaceutical manufact

Description: Pharma distributor Cencora has continued to outpace the broader market over the past year, and analysts remain strongly bullish on the stock’s prospects.

Description: Cencora is betting on the future of pharmaceutical logistics, announcing a $1 billion investment through 2030 to expand and modernize its U.S. distribution infrastructure. This move is not just network growth, but a shift aimed at supporting the rising demand of prescription medications and strengthening the reliability of the supply chain that delivers them. The […] The post Cencora makes $1 billion investment in pharma supply chains appeared first on FreightWaves.

Description: The second national distribution centre, which is in Harrison, Ohio, will be operational by spring 2027.

Description: Cencora (COR) posted a net profit margin of 0.6%, a notch below last year’s 0.7%, while earnings rose 2.2% in the latest period, a significant slowdown from its 48.8% average annual growth rate over the past five years. Looking ahead, analysts expect earnings to increase by 11.04% per year, trailing the broader US market’s 16%, with the top line forecast to grow 6.7% versus the market’s 10.5%. However, the results were overshadowed by a one-off loss of $713.2 million in the trailing 12 months...

Description: Healthcare distributor Cencora (NYSE:COR) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 5.9% year on year to $83.73 billion. Its non-GAAP profit of $3.84 per share was 1.4% above analysts’ consensus estimates.

Description: Cencora Inc (COR) reports robust growth in adjusted income and EPS, while navigating goodwill impairments and strategic realignments.

Description: RGTI's Q3 results are likely to gain from U.S. funding clarity, new contracts and gains from its next-gen quantum system.

Description: Cencora's Q4 results top estimates with 15% EPS growth and stronger margins, as GLP-1 demand and the RCA acquisition fuel solid segment gains.

Description: Bennett S. Murphy: Thank you. Good morning, good afternoon, and thank you for joining us for this conference call to discuss Cencora, Inc.'s fiscal 2025 fourth quarter and full year results. Joining me today are Robert P. Mauch, President and CEO, and James F. Cleary, Executive Vice President and CFO.

Description: Although the revenue and EPS for Cencora (COR) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Description: Cencora (COR) delivered earnings and revenue surprises of +1.32% and +0.69%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: The company will open two new distribution centers and expand a third as demand surges for GLP-1s and other refrigerated medications.

Description: CONSHOHOCKEN, Pa., November 05, 2025--Cencora, a global pharmaceutical solutions company, today announced plans to invest $1 billion through 2030 to bolster and expand its pharmaceutical distribution network in the United States. The investments — headlined by the opening of its second national distribution center in Ohio and an expanded presence in Alabama and California — will increase Cencora’s capacity, improve efficiency and enhance the resilience of its national distribution network, stren

Description: Healthcare distributor Cencora (NYSE:COR) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 5.9% year on year to $83.73 billion. Its non-GAAP profit of $3.84 per share was 1.4% above analysts’ consensus estimates.

Description: CONSHOHOCKEN, Pa. AP) — Cencora, Inc. COR) on Wednesday reported a loss of $339.7 million in its fiscal fourth quarter.

Description: CONSHOHOCKEN, Pa., November 05, 2025--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2025 fourth quarter ended September 30, 2025, revenue increased 5.9 percent to $83.7 billion. Revenue increased 9.3 percent to $321.3 billion for fiscal year 2025. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $(1.75) for the September quarter of fiscal 2025, compared to $0.02 in the prior year quarter. Adjusted diluted EPS, which is

Description: Agilon (AGL) delivered earnings and revenue surprises of -50.00% and +0.57%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Solventum's Q3 results may reflect softer sales and tariff impacts, though pricing discipline and core growth drivers likely aided margins.

Description: Dentsply Sirona's Q3 results may reveal ongoing softness in U.S. demand and orthodontic segments despite steady cost control.

Description: McKesson's Q2 results may show steadier growth as strong U.S. pharmaceutical and RxTS momentum drive its expanding top line.

Description: Healthcare distributor Cencora (NYSE:COR) will be reporting earnings this Wednesday before the bell. Here’s what you need to know.

Description: Humana, Cencora and Globus Medical are poised to outshine in the September quarter, driven by strong demand, innovation and volume growth.

Description: Evaluate the expected performance of Cencora (COR) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Description: Check out the companies making headlines this week:

Description: Shares of healthcare distributor Cencora (NYSE:COR) jumped 3.3% in the morning session after Mizuho analyst Steven Valiquette raised the price target on the company's shares. The price target was increased to $340 from $334, while the firm kept an 'Outperform' rating on the stock. This move signaled continued confidence in Cencora's market performance. Adding to the positive mood in the sector, a key peer, Cardinal Health, reported strong quarterly results and lifted its outlook for the year. Ca

Description: Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Description: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Description: Baxter's Q3 results are expected to show steady revenue growth led by Advanced Surgery and Drug Compounding, though IV fluid and anesthesia softness may weigh on EPS.

Description: The U.S. Cell and Gene Therapy Third-Party Logistics (3PL) Market is anticipated to surge from US$ 2.61 billion in 2024 to US$ 5.88 billion by 2033, maintaining a CAGR of 9.46% from 2025 to 2033. Key growth drivers include increased therapy adoption, specialized logistics needs, and expanding biopharmaceutical collaborations. Regulatory demands, cold chain technology adoption, and challenges such as logistics costs and workforce expertise underscore the market's evolution. States like California

Description: DentScribe.ai, the agentic AI platform that transforms dental SOAP notes into real-time clinical checklists and practice growth signals, today announced that Dr. Mandeep S. Dhalla, MD, has invested in the company and joined as a Strategic Advisor.

Description: Cencora (COR) shares continue to climb, gaining around 1% in the past day and up over 8% for the month. Investors seem to be weighing the company’s strong revenue and net income growth in light of broader market trends. See our latest analysis for Cencora. Cencora’s momentum is clearly building, with a 1-month share price return of 8% and the stock now up over 48% year to date. Its 1-year total shareholder return of 43% is even more impressive, reinforcing both near-term optimism and the...

Description: CAH's Pharmaceutical and Specialty units are expected to have fueled double-digit revenue growth in Q1 FY26 despite tariff and cost headwinds.

Description: UHS is likely to have posted Q3 revenue and earnings growth, driven by strong hospital and behavioral health segments despite cost pressures.

Description: Cencora is scheduled to release its fourth-quarter results next month, with analysts projecting double-digit earnings growth.

Description: Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Description: Earlier this week, Cycle Pharmaceuticals announced the launch of PHYRAGO, a new oncology therapy for leukemia, developed with Handa Therapeutics and made exclusively available in the US through Onco360® and a specialty distribution network that includes McKesson. This collaboration provides McKesson with a valuable commercial opportunity as an exclusive distributor for a newly introduced specialty oncology product in high-need therapeutic areas. We'll explore how McKesson's participation in...